// App-Quantinova.ai

OP0024 (2022) : DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PsA 1 AND SELECT-PsA 2 STUDIES

Researchers

Presenter

  • F. Cai

Principal Investigators

  • T. Sornasse

  • M. Ruzek

  • Y. Fang

  • K. Kato

  • P. Wung

  • I. McInnes

Medical Centers

  • AbbVie, Precision Medicine - Immunology, South San Francisco, United States of America

  • AbbVie, Discovery - Immunology, Worcester, United States of America

  • AbbVie, DMPK-BA, South San Francisco, United States of America

  • AbbVie Inc, Immunology, Illinois, United States of America

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Interleukin 17A

  • Malondialdehyde

  • Interleukin 6

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved